Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts’ voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas.
腹膜肉瘤病是一种罕见的恶性疾病，预后较差，继发于腹盆腔软组织肉瘤的腹膜播散。其罕见性，加上组织学异质性的特点以及历史上对全身治疗反应不佳，阻碍了建立广泛接受的根治性治疗标准。在这方面，广泛用于腹膜癌病并取得优异效果的根治性细胞减灭术（CRS）联合腹膜切除术和腹腔热灌注化疗（HIPEC），在腹膜肉瘤病患者中并未取得同样的进展。一个由肉瘤和腹膜肿瘤外科专家组成的多学科工作组，根据当前科学证据，针对腹膜肉瘤病的治疗制定了一系列建议，并考虑了可能引发该病的不同腹盆腔肉瘤组织学亚群，根据其起源分为：腹膜后肉瘤、子宫肉瘤以及源自胃肠道间质瘤（GIST）和非GIST来源的脏器/腹膜肉瘤。本文展示了在近期举行的第三届西班牙-葡萄牙肉瘤治疗更新会议上，于第一届伊比利亚-美洲腹膜肉瘤病管理共识会议期间，肉瘤专家们对提出的建议进行投票的结果。
肿瘤(癌症)患者之家